all report title image
  • Published In : May 2024
  • Code : CMI7002
  • Pages :174
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Size and Trends

Global dyslexia treatment market is estimated to be valued at USD 7.59 Bn in 2024 and is expected to reach USD 11.74 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Dyslexia Treatment Market Key Factors

To learn more about this report, request a free sample copy

Increasing prevalence of dyslexia disorders globally and rising awareness about its identification and management are expected to drive the market growth. According to recent estimates, around 10%–17% of the population has some form of dyslexia. As dyslexia can negatively impact academic and professional opportunities, there has been growing demand for effective interventions and accommodations. Furthermore, technological advancements have led to introduction of assistive devices and software that can help in screening, diagnosis and treatment of dyslexia, thus, driving the market growth. However, high treatment costs associated with dyslexia management can hamper the market growth in low-income regions.

Market Driver –Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, in November 2022, Hospices Civils de Lyon, a hospital in France, initiated the assessment of visual dyslexia remediation protocols - dyslexia REMEDIATION and it is estimated to complete by February 2025.

Market Concentration and Competitive Landscape

Dyslexia Treatment Market Concentration By Players

To learn more about this report, request a free sample copy

Growing Awareness and Social Acceptance of Dyslexia

With greater understanding about dyslexia as a neurological condition rather than an intelligence or capability issue, more families and children are openly discussing experiences of dyslexia. Educational institutions have also played a role in promoting dyslexia awareness through specialist programs, screening efforts, and accommodation policies. Societal attitudes are gradually shifting from seeing dyslexia as a stigma towards acceptance as a normal variation in learning styles. Individuals with dyslexia are now more comfortable self-identifying and seeking formal evaluation and treatment. Past attitudes that read dyslexia as laziness or lack of effort are diminishing. This has encouraged more families worldwide to proactively address dyslexia concerns in children rather than ignoring signs. Heightened social consciousness boosts the need for dyslexia-tailored therapies, tutoring services and educational resources. Public discussions and activism spearheaded by prominent dyslexic achievers have inspired hope in others struggling with dyslexia. Their success stories challenge misconceptions and reduce the fear of stigmatization associated with identification and management of dyslexia. 

Key Takeaways from Analyst

Global dyslexia treatment market is expected to witness growth in the near future due to rising awareness about learning disabilities like dyslexia among parents and patients. This increased awareness is expected to drive more people to seek formal diagnoses and treatment options. Furthermore, as diagnosis and treatment becomes more mainstream, the social stigma around dyslexia decreases, making people more comfortable seeking help.

High treatment costs can hamper the market growth, as dyslexia therapies can be a financial burden. Ongoing research into lower-cost and more accessible treatment models could help overcome this barrier. The development of digital therapy tools and apps also offers opportunities to make dyslexia treatment more affordable and convenient.

North America currently dominates the global dyslexia treatment market due to strong healthcare infrastructure and growing screening programs in schools. However, Asia Pacific is expected to witness the fastest growth over the forecast period. Countries like China and India are investing heavily in education and have large populations, thus, creating opportunities for treatment providers. Growing private healthcare expenditure in Asia will boost market expansion.

Market Challenge – Lack of Trained Professionals

The lack of trained professionals can hamper the global dyslexia treatment market growth. Dyslexia is a learning disorder that causes difficulty with reading, writing and spelling despite normal intelligence. It affects the ability of an individual to fluently decode and understand written words. However, with proper diagnosis and treatment, people with dyslexia can learn compensatory strategies to overcome its challenges.

Market Opportunity – Online Learning Platforms

Online learning platforms can revolutionize the dyslexia treatment market globally. With technological advancements, more affordable devices and improved connectivity, online learning is becoming accessible to students across the world. This opens up possibilities for treating dyslexia that were previously limited by physical or financial barriers. Online platforms allow students to access individually tailored, multi-sensory dyslexia treatment programs from the comfort of their own homes. Teachers and clinicians can create personalized lesson plans, assessments and feedback mechanisms for each student based on their specific needs and challenges. Treatment sessions and assignments can be completed on a flexible schedule in a stress-free environment. This makes therapy more engaging and enjoyable for students. Platforms incorporate gamification elements and utilize tools like videos, audio, interactive activities and games to make learning fun. Teachers are able to monitor progress closely and modify or enhance lessons in real-time.

Dyslexia Treatment Market By Type

To learn more about this report, request a free sample copy

Insights, By Type: Phonological interventions drives the phonological dyslexia segment growth

Type segment is sub-segmented into phonological dyslexia, surface dyslexia, double deficit dyslexia, and others. Phonological dyslexia sub-segment is estimated to hold 35.8% of the market share in 2024, owing to the availability of effective phonological interventions. Phonological dyslexia is characterized by difficulties in manipulating the sounds in words, such as blending, segmenting, or rhyming. It is the most common subtype of dyslexia that makes up around 70% of cases. Various phonological interventions have proven effective at improving reading abilities in individuals with phonological dyslexia. Phonological awareness training involves teaching patients to recognize and consciously manipulate the sounds within words. This  strengthen phonological processing abilities and coding of grapheme-phoneme correspondences. Structured literacy programs that emphasize the phonics approach to reading instruction have also yielded positive results. Devices utilizing speech synthesis and phonological prompts allow patients to practice sound-symbol associations in a multisensory manner. Computer-assisted programs break down this process further with colorful graphics and game elements to enhance engagement. Widespread availability and recommendation of such interventions by healthcare professionals and educators boosts market share of phonological dyslexia.

Insights, By Application: Antihistamines segment dominates due to wide clinical applications

Application segment is sub-segmented into antihistamines, central nervous stimulant, selective norepinephrine reuptake inhibitors, and others. Antihistamines sub-segment is estimated to hold 42.2% of the market share in 2024, due to their wide range of clinical applications. While dyslexia itself is not considered an allergic or inflammatory condition, several antihistamines have shown efficacy in improving core dyslexia symptoms. Histamine receptor antagonists like cetirizine are frequently prescribed off-label to boost phonological skills and reading fluency in patients. Their sedative effects are believed to minimize distractions and promote focused attention during language tasks. Selective second-generation antihistamines impact norepinephrine and serotonin levels in the brain and this  modulates dopamine and acetylcholine activity crucial for learning, memory formation, and visual processing abilities impaired in dyslexia. The neurological mechanisms through which antihistamines mediate their effects are still under research. However, their favorable safety profile, established use in other CNS conditions, and oral administration contribute to strong preference over other drug classes by clinicians and patients. This sustains antihistamines as the foremost treatment approach according to the provided drug class segmentation.

Insights, By Distribution Channel: Access and compliance favors hospital pharmacies

Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies sub-segment is estimated to hold 52.9% of the market share in 2024, owing to factors of access and compliance. Most dyslexia cases are managed in outpatient hospital settings by pediatricians, neurologists, or child psychiatrists. This facilitates seamless prescribing and dispensing of medications directly from hospital outpatient pharmacies. Obtaining long-term prescriptions from retail or online sources requires frequent refills that can pose adherence challenges, thus, hospital pharmacies encourage treatment continuity and address issues through direct counseling. These also play a critical role in supervising complex dosing schedules for pediatric patients and addressing insurance paperwork. This level of oversight and accessibility boosts medication adherence substantially compared to other channels.

Regional Insights

Dyslexia Treatment Market Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global dyslexia treatment market and is estimated to hold 34.1% of the market share in 2024. The U.S., being home to some of the most advanced healthcare infrastructure and research capabilities, has been at the forefront in dyslexia diagnostics and therapies. Leading pharmaceutical companies have their headquarters in the U.S., and have invested significantly in developing new drugs and technologies for dyslexia treatment. Moreover, there has been huge awareness and screening for learning disabilities like dyslexia in the U.S. Several non-profit organizations actively work to educate parents and teachers about identifying the early signs of dyslexia in children. As a result, many dyslexic individuals are diagnosed at a young age and receive remedial support through special education programs and tutoring. This early intervention has boosted demand for various dyslexia treatment solutions.

Asia Pacific region, led by China and India, has emerged as the fastest growing market for dyslexia treatment. While awareness and formal diagnosis of dyslexia has traditionally been lower as compared to Western nations, this is rapidly changing. Individuals and parents in major Asian countries have begun acknowledging learning disabilities more openly. Governments are also allocating greater funding towards special education, and have partnered with international experts to enhance teacher training programs. The booming economy in the region has also helped to improve affordability and accessibility of dyslexia treatment in Asia Pacific. Local pharmaceutical players as well as multinational companies have set up manufacturing facilities as well as research centers to cater to the burgeoning demand. Furthermore, e-commerce has made screening and diagnostic tools more convenient to obtain. With its massive population and rising disposable incomes, the Asia Pacific region is well-positioned to drive the next phase of growth of global dyslexia treatment market.

Market Report Scope

Dyslexia Treatment Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 7.59 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 6.4% 2031 Value Projection: US$ 11.74 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Type: Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia, Others
  • By Drug Class: Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reuptake Inhibitors, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, Astrazeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Lupin

Growth Drivers:
  • Increasing Research and Development Activities by Key Market Players
  • Growing Awareness and Social Acceptance of Dyslexia 
Restraints & Challenges:
  • Lack of Trained Professionals
  • Social Stigma 

Key Developments

  • In October 2023, Institut Pasteur, a research organization in France, announced that it had started evaluation of speech rhythm training in dyslexic readers aged 7 to 9 years. The estimated study completion date is July 2025.
  • In October 2023, Understood for All, Inc., a nonprofit healthcare organization, announced the launch of "The Many Faces of Learning Disabilities" campaign in U.S. for learning and thinking differences, like ADHD and dyslexia. This social media campaign aims to spotlight a range of personal stories from neurodivergent individuals conveying that learning disabilities are more common
  • In December 2022, Kyndryl, the largest IT infrastructure services provider in Canada and the world, announced a partnership with Dyslexia Canada, a national charity formed in 2016 to advocate for all Canadian children with dyslexia. Kyndryl and Dyslexia Canada will work together to increase awareness about challenges faced by children and youth with dyslexia, and to collaborate on helping those with dyslexia.
  • In June 2020, Otsuka Holdings Co., Ltd., a pharmaceutical company, announced the positive top-line results from two, six-week, phase 3 clinical trials that evaluated the efficacy, safety and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention-deficit hyperactivity disorder (ADHD)

*Definition: Dyslexia is a learning disability that affects an individual's ability to read, write, and spell. It is characterized by difficulties with phonological awareness, verbal memory, and verbal processing speed, which can impede accurate and fluent word reading and spelling. Dyslexia is a neurodevelopmental disorder that is not related to intelligence, and it can co-occur with other conditions such as attention deficit hyperactivity disorder (ADHD). Dyslexia is typically diagnosed through a comprehensive evaluation that considers various cognitive, behavioral, emotional, and environmental factors. The assessment may involve a series of tests, including those that evaluate phonological awareness, verbal memory, and reading and spelling abilities.

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Phonological Dyslexia
    • Surface Dyslexia
    • Double Deficit Dyslexia
    • Others
  •  Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
    • Antihistamines
    • Central Nervous Stimulant
    • Selective Norepinephrine Reuptake Inhibitors
    • Others
  •  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Jubilant Pharma Limited
    • GSK plc
    • Eli Lilly and Company
    • Otsuka Holdings Co., Ltd.
    • Apotex Corporation
    • Purdue Pharma
    • Rhodes Pharmaceuticals L.P.
    • Cian Healthcare Pvt. Ltd.
    • Wallace Pharmaceuticals Ltd.
    • The Himmel Group
    • Astrazeneca
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Lupin

Frequently Asked Questions

The CAGR of global dyslexia treatment market is projected to be 6.4% from 2024 to 2031.

Increasing research and development activities by key market players and growing awareness and social acceptance of dyslexia are the major factors driving the growth of global dyslexia treatment market.  

Lack of trained professionals and social stigma are the major factors hampering the growth of global dyslexia treatment market.  

In terms of type, phonological dyslexia segment is estimated to dominate the market in 2024.

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, Astrazeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Lupin are the major players.

North America is expected to lead the global dyslexia treatment market.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo